IMS Pharmaceutical Pricing & Reimbursement Concise Guide: France

  • ID: 1408481
  • Report
  • Region: France
  • 83 Pages
  • IMS Health
1 of 3
The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.
Note: Product cover images may vary from those shown
2 of 3
1. Healthcare System
Facts & Figures
Market Indicators
Provision & Funding
Overview
Statutory Health Insurance System
Complementary Health Insurance
Funding
Background
Healthcare Reform Law

2. Pricing
Prescription Drugs
Overview
Standard Pricing Procedure
Accelerated Pricing Procedure
Health Economic Evaluation
Conditional Pricing
Pricing Agreements
Price Caps
Hepatitis C Drugs
Price Levels
Generic Drugs
Pricing Rules
Pricing Procedure
Hospital Drugs
T2A System
T2A Exclusions and Liste de Rétrocession
ATU/post-ATU
Actual Prices
OTC Drugs
Reimbursed OTCs
Non-reimbursed OTCs

3. Reimbursement
Admission to Reimbursement
Patient Participation
Role of the CT
Application Process
Medical Benefit Rating Systems
Assessment
Decision
Final Decision
Restricted Reimbursement
Proposed New Evaluation System
Reimbursement Categories
Full Reimbursement
Standard Reimbursement
Proposed Changes
Reimbursement Prices
Reference Price Reimbursement System
Hospital Reimbursement
Hospital Supply Authorisation
Formularies
Funding
Changes in Reimbursement Status
Five-year Reviews
Exceptional Reviews
Changes to Reimbursed Indications
Reimbursement Rate Changes
Delistings
Changes in Reimbursement Prices
European Price Guarantee
Five-year Reviews
Off-patent Originals and Generics
Price Consistency
Targeted Price Cuts
Other Price Cuts/Revisions
Price Increases

4. Pharmacoeconomics
Pharmacoeconomic Requirements
Mandatory HE Evaluations
Other HE Evaluations

5. Price Build Up
Wholesalers
Margins
Discounts
Social Security Contribution
Background
Drug Shortages
Supply Chain Investigation
Retail Pharmacies
Margins
Discounts
Background
Dispensing Doctors
Sales Tax

6. Cost Containment
Industry Paybacks
Turnover-based Tax
Clause de Sauvegarde
Conventions System
Hepatitis C Medicines
Temporary Use Drugs
Promotional Costs
Promotion-based Tax
Advertising
Sales Reps
Sunshine Act
Patient Co-payments
Pharmaceuticals
Out-patient Care
In-patient Care
Prescribing Controls
Prescribing Targets
Guidelines
Exception Drugs
Feedback
Campaigns
Prescribing Restrictions
Off-label Prescribing
Generics
National Action Plan
Generic Substitution
INN Prescribing
Prescribing Targets
Generic and Off-patent Price Cuts
Biosimilars
Rx-to-OTC Switches
Switches
Easier Patient Access to OTCs
OTC Sales
Parallel Trade
Parallel Exports
Parallel Imports

7. Future Developments
Outlook
LFSS 2017
Liste en Sus
Generic Pricing
Reimbursement Rates
Pharmacy Convention
Accord Cadre
Proposed New Evaluation Systems

8. Names & Addresses
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll